CellPhire: Funding, Investors & Team (Oct 2026)
Cellphire has developed a proprietary method for the stabilization of blood in the dry state Current efforts and product development are aimed toward stabilized platelets for advanced wound care, transfusion, and reagent products for clinical and research diagnostics. We have been able to stabilize and modify platelets into a hemostatic agent that can be stored well beyond the current limit of 5 days. Platelets cannot be stockpiled and shortages occur because of this extremely short shelf life. These shortages can interrupt the treatment of cancer patients and actively bleeding surgical or trauma patients. The fragility of the national supply of platelets is a topic of discussion of several task forces and agencies planning the nation's response to a pandemic such as avian influenza. This and other natural or manmade disasters would interrupt or exceed the available supply of platelets that is needed to maintain an adequate supply or treat bleeding casualties.
CellPhire has raised $2.0M across 1 funding round on record, the most recent an undisclosed round of $2.0M announced in Oct 2023.
That round is below the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
CellPhire Company Profile and Key Stats
Latest funding round on record: Oct 2023.
CellPhire Funding Rounds
CellPhire Founders and Leadership Team
Contact details for the CellPhire team: 1 of 1 has an email address on file.
Start 14-day free trial →CellPhire Funding Compared to Other Biotechnology Startups
CellPhire's latest round of $2.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like CellPhire in Biotechnology and Rockville
Companies Similar to CellPhire
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
CellPhire Funding FAQs
What does CellPhire do?
Cellphire has developed a proprietary method for the stabilization of blood in the dry state Current efforts and product development are aimed toward stabilized platelets for advanced wound care, transfusion, and reagent products for clinical and research diagnostics. We have been able to stabilize and modify platelets into a hemostatic agent that can be stored well beyond the current limit of 5 days. Platelets cannot be stockpiled and shortages occur because of this extremely short shelf life. These shortages can interrupt the treatment of cancer patients and actively bleeding surgical or trauma patients. The fragility of the national supply of platelets is a topic of discussion of several task forces and agencies planning the nation's response to a pandemic such as avian influenza. This and other natural or manmade disasters would interrupt or exceed the available supply of platelets that is needed to maintain an adequate supply or treat bleeding casualties.
How much funding has CellPhire raised?
CellPhire has raised $2.0M across 1 round on record. The most recent is an undisclosed round of $2.0M announced in Oct 2023.
When did CellPhire last raise funding?
CellPhire's most recent funding round on record is an undisclosed round of $2.0M, announced in Oct 2023.
Who is the CEO of CellPhire?
Mike Gaffney is listed as CEO at CellPhire.
Where is CellPhire headquartered?
CellPhire is based in Rockville, Maryland, United States.
How many employees does CellPhire have?
CellPhire is in the 51-100 employee band.
How does CellPhire's funding compare to other Biotechnology startups?
CellPhire's latest round of $2.0M is below the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's CellPhire Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CellPhire is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.